Lipiodol¡¯s price reduced from 25th... 2-year suit dismissed
By Kim, Jung-Ju | translator Alice Kang
22.09.24 06:00:32
°¡³ª´Ù¶ó
0
The suspension of execution allowed the price discount automatically terminated with the end of the lawsuit
The price of Guerbet Korea¡¯s liver cancer contrast medium, Lipiodol Ultra-Fluid (iodized oil, 12.8g/10mL), which had been under legal dispute for the past 2 years after the government decided to remove the drug from the reimbursement list, will be reduced from the 25th this month.
This is because the pricing discount that had been originally made by the government was reapplied upon the court¡¯s dismissal of the lawsuit and the automatic termination of suspension of execution that followed.
On the 19th, the Seoul High Court¡¯s Administrative Court Department 6-1 decided to dismiss the administrative lawsuit filed by Guerbet Korea and notified the company and the MOHW of the ter
Kim, Jung-Ju(jj0831@dailypharm.com)
If you want to see the full article, please JOIN US (click)